Thozalinone (Stimsen) has been used as an antidepressant in Europe and has also been trialed as an anorectic. It acts via inducing the release of norepinephrine and dopamine as with its analogues pemoline and aminorex. Thozalinone has been shown to possess some pharmacologic actions similar to those of amphetamine and imipramine, but with important differences. It is less toxic than amphetamine, and its margin of safety in mice is greater. The stimulant action does not progress to tremors or convulsions as the dosage is increased. The anorexigenic activity of thozalinone is more pronounced and longer lasting than that of amphetamine. There is no evidence of the development of tolerance. The cardiovascular side effects of thozalinone are minimal, and analeptic actions are absent.